Insilico Medicine's AI-Discovered Drug Rentosertib Shows Biological Age Reversal in Phase IIa Trial, Published in Nature Biotechnology

Insilico Medicine's AI-designed drug, rentosertib, was associated with a younger predicted biological age in a Phase IIa trial subgroup, with results published in Nature Biotechnology on September 7, 2026. The study found an apparent biological age reversal of roughly 3–4 years at week four in the 30 mg twice-daily arm, with one clock showing up to six years. These findings will be presented by first author Alex Zhavoronkov at the Sorbonne on September 8, 2026. For broader context, explore our AI Tools by Platform.

AI-Driven Drug Discovery for Idiopathic Pulmonary Fibrosis

Rentosertib is a TNIK inhibitor initially developed for idiopathic pulmonary fibrosis (IPF). Its target and molecular structure were identified using Insilico Medicine's proprietary AI platforms, PandaOmics and Chemistry42. This AI-driven approach allowed for the rapid discovery and development of the compound, which has since progressed to Phase III clinical trials for IPF.

The successful advancement of rentosertib highlights the growing impact of artificial intelligence in pharmaceutical research. Platforms like PandaOmics and Chemistry42 use advanced algorithms to analyze vast datasets, predict disease targets, and design novel molecules, significantly accelerating the drug discovery process. For more information on how AI is transforming drug development, explore our AI news section.

Exploratory Analysis of Biological Age Markers

The biological age reversal observations stem from a secondary proteomic analysis conducted on a 42-patient subgroup of the Phase IIa trial. This analysis benchmarked the proteomic profiles against 55,319 UK Biobank profiles to assess changes in biological age markers. While the results are compelling, the authors emphasize that this analysis was exploratory and does not constitute definitive proof of longevity or a direct anti-aging effect.

The study represents one of the first instances where human clinical data suggests an AI-discovered drug can favorably influence aging-related protein biomarkers. This finding opens new avenues for research into the broader implications of drugs developed for specific diseases on systemic biological processes, including those associated with aging.

Implications for Future Research and AI in Healthcare

The publication of these findings in a prestigious journal like Nature Biotechnology underscores the scientific community's interest in the potential of AI-driven drug discovery to address complex health challenges. While rentosertib's primary indication remains IPF, the observed effects on biological age markers warrant further investigation.

The ongoing Phase III trials for IPF will provide more comprehensive data on rentosertib's efficacy and safety. Future research may also explore the mechanisms behind the observed biological age reversal and whether these effects can be replicated and sustained in larger, dedicated studies. The integration of AI platforms in drug development continues to evolve, promising more targeted and efficient therapeutic solutions across various medical fields.

Conclusion

Insilico Medicine's rentosertib, an AI-discovered drug, has shown an association with a younger predicted biological age in an exploratory Phase IIa trial subgroup, with effects ranging from 3–4 years of reversal. These findings, published in Nature Biotechnology, highlight the potential of AI platforms like PandaOmics and Chemistry42 in identifying novel drug candidates with unexpected systemic benefits. While the analysis is exploratory and not proof of longevity, it marks a significant step in demonstrating how AI-driven drug discovery can impact not only specific diseases but also broader biological processes related to aging. The drug's progression to Phase III for IPF will provide further insights into its overall therapeutic profile.

Sources

• [PDF] Summary - arXiv
• drug-discovery-bispecific-agents/DESIGN.md at main - GitHub
• AI drug discovery platform Insilico Medicine announces $255 million in Series C funding | TechCrunch
• Nature Biotechnology | Insilico’s AI-Driven IPF Candidate Rentosertib Shows Potential for Biological Age Reversal, as Assessed by Six Proteomic Aging Clocks
• Nature Biotechnology | Insilico's AI-Driven IPF Candidate Rentosertib Shows Potential for Biological Age Reversal, as Assessed by Six Proteomic Aging Clocks